Genetic risk, adherence to healthy lifestyle and acute cardiovascular and thromboembolic complications following SARS-COV-2 infection.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
03 08 2023
03 08 2023
Historique:
received:
21
12
2022
accepted:
19
07
2023
medline:
7
8
2023
pubmed:
4
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
Current understanding of determinants for COVID-19-related cardiovascular and thromboembolic (CVE) complications primarily covers clinical aspects with limited knowledge on genetics and lifestyles. Here, we analysed a prospective cohort of 106,005 participants from UK Biobank with confirmed SARS-CoV-2 infection. We show that higher polygenic risk scores, indicating individual's hereditary risk, were linearly associated with increased risks of post-COVID-19 atrial fibrillation (adjusted HR 1.52 [95% CI 1.44 to 1.60] per standard deviation increase), coronary artery disease (1.57 [1.46 to 1.69]), venous thromboembolism (1.33 [1.18 to 1.50]), and ischaemic stroke (1.27 [1.05 to 1.55]). These genetic associations are robust across genders, key clinical subgroups, and during Omicron waves. However, a prior composite healthier lifestyle was consistently associated with a reduction in all outcomes. Our findings highlight that host genetics and lifestyle independently affect the occurrence of CVE complications in the acute infection phrase, which can guide tailored management of COVID-19 patients and inform population lifestyle interventions to offset the elevated cardiovascular burden post-pandemic.
Identifiants
pubmed: 37537214
doi: 10.1038/s41467-023-40310-0
pii: 10.1038/s41467-023-40310-0
pmc: PMC10400557
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4659Informations de copyright
© 2023. Springer Nature Limited.
Références
Nat Rev Cardiol. 2022 May;19(5):291-301
pubmed: 34811547
Nature. 2022 Jul;607(7917):97-103
pubmed: 35255492
N Engl J Med. 2016 Dec 15;375(24):2349-2358
pubmed: 27959714
JAMA. 2022 Jul 26;328(4):367-374
pubmed: 35881115
Z Gesundh Wiss. 2023;31(2):267-275
pubmed: 33558839
Lancet Infect Dis. 2022 Aug;22(8):1142-1152
pubmed: 35576963
J Am Coll Cardiol. 2021 Jul 6;78(1):56-65
pubmed: 34210415
JCI Insight. 2021 Jul 8;6(13):
pubmed: 34061779
Lancet. 2015 Jun 6;385(9984):2264-2271
pubmed: 25748612
JAMA. 2022 Jul 26;328(4):375-388
pubmed: 35881116
Microb Genom. 2020 Jul;6(7):
pubmed: 32553051
N Engl J Med. 2020 Oct 15;383(16):1522-1534
pubmed: 32558485
Circ Heart Fail. 2020 Jul;13(7):e007220
pubmed: 32500721
JAMA Psychiatry. 2021 Jan 1;78(1):101-109
pubmed: 32997097
Gut. 2021 Nov;70(11):2096-2104
pubmed: 34489306
Cells. 2020 Nov 19;9(11):
pubmed: 33228225
BMJ. 2018 Oct 24;363:k4168
pubmed: 30355576
JAMA Intern Med. 2022 Oct 1;182(10):1063-1070
pubmed: 35980616
Stat Med. 2010 Apr 30;29(9):1037-57
pubmed: 20087875
Thromb Haemost. 2022 Sep;122(9):1549-1557
pubmed: 35623617
JAMA Cardiol. 2018 Aug 1;3(8):693-702
pubmed: 29955826
JAMA. 2021 Apr 27;325(16):1613-1615
pubmed: 33734290
Nature. 2018 Oct;562(7726):203-209
pubmed: 30305743
JAMA Intern Med. 2023 Mar 1;183(3):232-241
pubmed: 36745445
Eur J Prev Cardiol. 2022 Feb 19;29(1):5-115
pubmed: 34558602
BMC Cardiovasc Disord. 2022 Mar 9;22(1):93
pubmed: 35264107
JAMA. 2020 Feb 18;323(7):636-645
pubmed: 32068818
JAMA. 2020 Feb 18;323(7):627-635
pubmed: 32068817
JAMA Intern Med. 2022 Oct 1;182(10):1082-1088
pubmed: 35994254
Nature. 2008 Feb 21;451(7181):914-8
pubmed: 18288180
Nat Commun. 2019 Dec 20;10(1):5819
pubmed: 31862893
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
Circulation. 2022 Aug 23;146(8):e93-e118
pubmed: 35862132
J Am Med Inform Assoc. 2019 Dec 1;26(12):1545-1559
pubmed: 31329239
Lancet Public Health. 2018 Dec;3(12):e576-e585
pubmed: 30467019
Lancet Digit Health. 2019 May 20;1(2):e63-e77
pubmed: 31650125
Nat Med. 2021 Nov;27(11):1876-1884
pubmed: 34782789
Cardiovasc Res. 2020 Aug 1;116(10):1666-1687
pubmed: 32352535